Search

Your search keyword '"Yip, Sonia"' showing total 175 results
Start Over Author "Yip, Sonia"
175 results on '"Yip, Sonia"'

1. A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE

Author

Tan, Lavinia, Brown, Chris, Mersiades, Antony, Lee, Chee Khoon, John, Thomas, Kao, Steven, Newnham, Genni, O’Byrne, Kenneth, Parakh, Sagun, Bray, Victoria, Jasas, Kevin, Yip, Sonia, Wong, Stephen Q., Ftouni, Sarah, Guinto, Jerick, Chandrashekar, Sushma, Clarke, Stephen, Pavlakis, Nick, Stockler, Martin R., Dawson, Sarah-Jane, and Solomon, Benjamin J.

Published
2024
Full Text
View/download PDF

2. NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma

Author

Sim, Hao-Wen, Wachsmuth, Luke, Barnes, Elizabeth H, Yip, Sonia, Koh, Eng-Siew, Hall, Merryn, Jennens, Ross, Ashley, David M, Verhaak, Roel G, Heimberger, Amy B, Rosenthal, Mark A, Hovey, Elizabeth J, Ellingson, Benjamin M, Tognela, Annette, Gan, Hui K, Wheeler, Helen, Back, Michael, McDonald, Kerrie L, Long, Anne, Cuff, Katharine, Begbie, Stephen, Gedye, Craig, Mislang, Anna, Le, Hien, Johnson, Margaret O, Kong, Benjamin Y, Simes, John R, Lwin, Zarnie, and Khasraw, Mustafa

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Aging, Rare Diseases, Cancer, Immunization, Clinical Research, Brain Cancer, Clinical Trials and Supportive Activities, Brain Disorders, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, clinical trials, glioblastoma, immunotherapy, older cancer patients, systemic therapy
Abstract

BackgroundThere is an immunologic rationale to evaluate immunotherapy in the older glioblastoma population, who have been underrepresented in prior trials. The NUTMEG study evaluated the combination of nivolumab and temozolomide in patients with glioblastoma aged 65 years and older.MethodsNUTMEG was a multicenter 2:1 randomized phase II trial for patients with newly diagnosed glioblastoma aged 65 years and older. The experimental arm consisted of hypofractionated chemoradiation with temozolomide, then adjuvant nivolumab and temozolomide. The standard arm consisted of hypofractionated chemoradiation with temozolomide, then adjuvant temozolomide. The primary objective was to improve overall survival (OS) in the experimental arm.ResultsA total of 103 participants were randomized, with 69 in the experimental arm and 34 in the standard arm. The median (range) age was 73 (65-88) years. After 37 months of follow-up, the median OS was 11.6 months (95% CI, 9.7-13.4) in the experimental arm and 11.8 months (95% CI, 8.3-14.8) in the standard arm. For the experimental arm relative to the standard arm, the OS hazard ratio was 0.85 (95% CI, 0.54-1.33). In the experimental arm, there were three grade 3 immune-related adverse events which resolved, with no unexpected serious adverse events.ConclusionsDue to insufficient evidence of benefit with nivolumab, the decision was made not to transition to a phase III trial. No new safety signals were identified with nivolumab. This complements the existing series of immunotherapy trials. Research is needed to identify biomarkers and new strategies including combinations.

Published
2023

3. CTLA4 protects against maladaptive cytotoxicity during the differentiation of effector and follicular CD4+ T cells

Author

Hao, Yuwei, Miraghazadeh, Bahar, Chand, Rochna, Davies, Ainsley R., Cardinez, Chelisa, Kwong, Kristy, Downes, Morgan B., Sweet, Rebecca A., Cañete, Pablo F., D’Orsogna, Lloyd J., Fulcher, David A., Choo, Sharon, Yip, Desmond, Peters, Geoffrey, Yip, Sonia, Witney, Matthew J., Nekrasov, Maxim, Feng, Zhi-Ping, Tscharke, David C., Vinuesa, Carola G., and Cook, Matthew C.

Published
2023
Full Text
View/download PDF

4. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Author

Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Sandhu, Shahneen, Kumar, Aravind Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia, Butler, Patrick, Zhang, Alison Yan, Yip, Sonia, Thomas, Hayley, Langford, Ailsa, Hofman, Michael S, McJannett, Margaret, Martin, Andrew James, Stockler, Martin R, and Davis, Ian D

Published
2024
Full Text
View/download PDF

6. INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)

Author

Lam, Lyn Ley, Pavlakis, Nick, Shitara, Kohei, Sjoquist, Katrin M., Martin, Andrew J., Yip, Sonia, Kang, Yoon-Koo, Bang, Yung-Jue, Chen, Li-Tzong, Moehler, Markus, Bekaii-Saab, Tanios, Alcindor, Thierry, O’Callaghan, Christopher J., Tebbutt, Niall C., Hague, Wendy, Chan, Howard, Rha, Sun Young, Lee, Keun-Wook, Gebski, Val, Jaworski, Anthony, Zalcberg, John, Price, Timothy, Simes, John, and Goldstein, David

Published
2023
Full Text
View/download PDF

7. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Author

Akhurst, Tim, Alipour, Ramin, Bailey, Dale, Banks, Patricia, Beaulieu, Alexis, Campbell, Louise, Crumbaker, Megan, Dhiantravan, Nattakorn, Hamid, Anis, Haskali, Mohammad, Hung, Terry, Kong, Grace, Lawrence, Nick, Lewin, Jeremy, McCarthy, Michael, Moodie, Kate, Murphy, Declan, Nguyen, Andrew, Pook, David, Ravi Kumar, Aravind, Roach, Paul, Roselt, Peter, Saghebi, Javad, Schembri, Geoff, Spain, Lavinia, Subramaniam, Shalini, Thang, Sue Ping, Thomas, Paul, Tran, Ben, Wallace, Roslyn, Yip, Sonia, Hofman, Michael S, Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Buteau, James P, Joshua, Anthony M, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ng, Siobhan, Francis, Roslyn J, Gedye, Craig, Rutherford, Natalie K, Weickhardt, Andrew, Scott, Andrew M, Lee, Sze-Ting, Kwan, Edmond M, Azad, Arun A, Ramdave, Shakher, Redfern, Andrew D, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Yan, Stockler, Martin R, Williams, Scott G, Martin, Andrew J, and Davis, Ian D

Published
2024
Full Text
View/download PDF

8. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial

Author

Abdi, Ehtesham, Allan, Suzanne, Bastick, Patricia, Begbie, Stephen, Blum, Robert, Briscoe, Karen, Brungs, Daniel, Bydder, Sean, Chittajallu, Bala Renuka, Cronk, Michelle, Cuff, Katharine, Davis, Ian D, Dowling, Anthony, Frydenberg, Mark, George, Matthew, Horvath, Lisa, Hovey, Elizabeth, Joshua, Anthony, Karanth, Narayan, Kichenadasse, Ganessan, Krieger, Laurence, Marx, Gavin, Mathlum, Maitham, Nott, Louise, Otty, Zulfiquer, Parnis, Francis, Pook, David, Sandhu, Shahneen, Sewak, Sanjeev, Stevanovic, Amanda, Stockler, Martin, Suder, Aneta, Tan, Hsiang, Torres, Javier, Troon, Simon, Underhill, Craig, Weickhardt, Andrew, Zielinski, Robert, Abbas, Tahir, Anan, Ghadeer, Booth, Chris, Campbell, Holly, Chi, Kim, Chin, Joseph, Chouinard, Edmond, Donnelly, Bryan, Drachenberg, Darrel, Faghih, Amir, Finelli, Antonio, Hotte, Sebastien, Noonan, Krista, North, Scott, Rassouli, Mohammad, Reaume, Neil, Rendon, Ricardo, Saad, Fred, Sadikov, Evgeny, Vigneault, Eric, Zalewski, Pawel, McCaffrey, John, McDermott, Ray, Morris, Patrick, O'Connor, Miriam, Donnellan, Paul, O'Donnell, Dearbhaile, Edwards, Jim, Fong, Peter, Tan, Alvin, Chowdhury, Simon, Crabb, Simon, Khan, Omar, Khoo, Vincent, Macdonald, Graham, Payne, Heather, Robinson, Angus, Shamash, Jonathon, Staffurth, John, Thomas, Carys, Thomson, Alastair, Sweeney, Christopher J, Martin, Andrew J, Stockler, Martin R, Cheung, Leanna, Chi, Kim N, Horvath, Lisa G, Joshua, Anthony M, Lawrence, Nicola J, McJannett, Margaret, North, Scott A, Parulekar, Wendy, Pook, David W, Reaume, Martin Neil, Sandhu, Shahneen K, Tan, Thean Hsiang, Vera-Badillo, Francisco, Williams, Scott G, Winter, Diana, Yip, Sonia, Zhang, Alison Y, and Zielinski, Robert R

Published
2023
Full Text
View/download PDF

9. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

Author

Akhurst, Tim, Alipour, Ramin, Azad, Arun A, Banks, Patricia, Beaulieu, Alexis, Buteau, James P, Chua, Wei, Davis, Ian D, Dhiantravan, Nattakorn, Emmett, Louise, Ford, Kate, Hofman, Michael S, Francis, Roslyn J, Gedye, Craig, Goh, Jeffrey C, Guminski, Alex, Hamid, Anis, Haskali, Mohammad B, Hicks, Rodney J, Hsiao, Edward, Iravani, Amir, Joshua, Anthony M, Kirkwood, Ian D, Kong, Grace, Kwan, Edmond M, Langford, Ailsa, Lawrence, Nicola, Lee, Sze-Ting, Lewin, Jeremy, Lin, Peter, Martin, Andrew J, McDonald, William, McJannett, Margaret M, Moodie, Kate, Murphy, Declan G, Ng, Siobhan, Pattison, David A, Pokorski, Izabella, Ramdave, Shakher, Ravi Kumar, Aravind S, Redfern, Andrew D, Rutherford, Natalie K, Saghebi, Javad, Sandhu, Shahneen, Scott, Andrew M, Spain, Lavinia, Stockler, Martin R, Subramaniam, Shalini, Tan, Thean Hsiang, Thang, Sue Ping, Tran, Ben, Wallace, Roslyn, Weickhardt, Andrew, Williams, Scott G, Yip, Sonia, and Zhang, Alison Y

Published
2022
Full Text
View/download PDF

11. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

Author

Nowak, Anna K, Lesterhuis, W Joost, Kok, Peey-Sei, Brown, Chris, Hughes, Brett GM, Karikios, Deme J, John, Thomas, Kao, Steven C-H, Leslie, Connull, Cook, Alistair M, Pavlakis, Nick, Briscoe, Karen, O'Byrne, Kenneth J, Karapetis, Christos S, Lam, Wei-Sen, Langford, Ailsa, Yip, Sonia, and Stockler, Martin R

Published
2020
Full Text
View/download PDF

12. MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)

Author

Siu, Ho Wai Derrick, Tebbutt, Niall, Chantrill, Lorraine, Karapetis, Chris, Steer, Christopher, Wilson, Kate, Espinoza, David, Bailey, Lisa, Yip, Sonia, Cuff, Jeff, Pavlakis, Nick, Thavaneswaran, Subotheni, Briscoe, Karen, Srivastav, Ratnesh, Shannon, Jennifer, Segelov, Eva, Tie, Jeannie, Caird, Susan, Francesconi, Alessandra, Price, Timothy, Wuttke, Melanie, Ladwa, Rahul, Sjoquist, Katrin, and Burge, Matthew

Published
2021
Full Text
View/download PDF

13. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer

Author

Oar, Andrew, Lee, Mark, Le, Hien, Wilson, Kate, Aiken, Chris, Chantrill, Lorraine, Simes, John, Nguyen, Nam, Barbour, Andrew, Samra, Jaswinder, Sjoquist, Katrin M., Moore, Alisha, Espinoza, David, Gebski, Val, Yip, Sonia, Chu, Julie, Kneebone, Andrew, and Goldstein, David

Published
2021
Full Text
View/download PDF

16. ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue.

Author

Mersiades, Antony J, Solomon, Benjamin J, Thomas, David M, Lee, Chee K, Cummins, Michelle M, Sebastian, Lucille, Ballinger, Mandy L, Collignon, Emily, Turnbull, Olivia MH, Yip, Sonia, Morton, Rachael L, Brown, Chris, Wheeler, Patrick J, Itchins, Malinda, Simes, R John, and Pavlakis, Nick

Abstract

ASPiRATION is a national prospective observational cohort study assessing the feasibility, clinical and economic value of up-front tissue-based comprehensive genomic profiling (CGP) to identify actionable genomic alterations in participants with newly diagnosed metastatic non-squamous non-small-cell lung cancer in Australia. This study will enrol 1000 participants with tumor available for CGP and standard of care molecular testing (EGFR/ALK/ROS1). Participants with actionable variants may receive novel targeted treatments through ASPiRATION-specific substudies, other trials/programs. Clinical outcome data will be collected for a minimum of 2 years. Study outcomes are descriptive, including the ability of CGP to identify additional actionable variants, leading to personalized treatment recommendations, and will describe the feasibility, efficiency, cost and utility of implementation of CGP nationally. Lung cancer is the most common cause of cancer death in Australia and worldwide. This disease often happens due to alterations in specific genes that allow cancer cells to develop and spread. Scientists have designed targeted drugs that are better at attacking cancer cells that have specific 'actionable' gene alterations and have less effect on other cells in the body. The result is often more benefit from treatment and fewer side effects than other standard treatments (chemotherapy or immunotherapy). The targeted drugs are well established as the best initial treatments for some gene alterations, but more research is needed to know if this is true for some of the less common or recently identified gene alterations, and where the targeted drugs are very new. Comprehensive genomic profiling is a new way of testing lung cancer cells for all the gene alterations (the well-known ones as well as the rare ones) in a single test. It is expected that this test will find many more of these gene alterations, which will allow more people to have safer and more effective targeted treatments leading to potentially better outcomes, and will allow some people to join clinical trials testing newer targeted treatments. The ASPiRATION study will help work out whether comprehensive genomic profiling is better than the current way of testing for gene alterations in Australia, and if it is feasible to use in all people diagnosed with advanced lung cancer in Australia. Clinical Trial Registration: ACTRN12621000221853 (ANZCTR) ASPiRATION is an Australian national prospective observational study assessing feasibility, clinical and economic value of comprehensive genomic profiling in newly diagnosed metastatic lung cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. NABNEC: A randomised phase II study of nab -paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas (GI-NECs).

Author

Chantrill, Lorraine A., Ransom, David, Chan, David, Nagrial, Adnan, Pavlakis, Nick, Markman, Ben, Karapetis, Christos Stelios, Sjoquist, Katrin Marie, Simes, John, Gebski, Val, Hofman, Michael S, Ginestet, Pablo Gonzalez, Gill, Anthony J., Yip, Sonia, Michael, Michael, Jaworski, Anthony, Siu, Ho Wai Derrick, and Khasraw, Mustafa

Published
2024
Full Text
View/download PDF

18. ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue

Author

Mersiades, Antony J, primary, Solomon, Benjamin J, additional, Thomas, David M, additional, Lee, Chee K, additional, Cummins, Michelle M, additional, Sebastian, Lucille, additional, Ballinger, Mandy L, additional, Collignon, Emily, additional, Turnbull, Olivia MH, additional, Yip, Sonia, additional, Morton, Rachael L, additional, Brown, Chris, additional, Wheeler, Patrick J, additional, Itchins, Malinda, additional, Simes, R John, additional, and Pavlakis, Nick, additional

Published
2023
Full Text
View/download PDF

19. INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG).

Author

Pavlakis, Nick, primary, Shitara, Kohei, additional, Sjoquist, Katrin Marie, additional, Martin, Andrew James, additional, Jaworski, Anthony, additional, Yip, Sonia, additional, Bang, Yung-Jue, additional, Alcindor, Thierry, additional, O'Callaghan, Christopher J., additional, Tebbutt, Niall C., additional, Strickland, Andrew, additional, Rha, Sun Young, additional, Lee, Keun-Wook, additional, Zalcberg, John Raymond, additional, Price, Timothy Jay, additional, Simes, John, additional, and Goldstein, David, additional

Published
2023
Full Text
View/download PDF

20. CTLA4 protects against maladaptive cytotoxicity during differentiation of effector and follicular CD4+ T cells

Author

Cook, Matthew, primary, Hao, Yuwei, additional, Miraghazadeh, Bahar, additional, Chand, Rochna, additional, Davies, Ainsley, additional, Cardinez, Chelisa, additional, Kwong, Kristy, additional, Downes, Morgan, additional, Sweet, Rebecca, additional, Cañete, Pablo, additional, D’Orsogna, Lloyd, additional, Fulcher, David, additional, Choo, Sharon, additional, Yip, Desmond, additional, Peters, Geoffrey, additional, Yip, Sonia, additional, Witney, Matthew, additional, Nekrasov, Maxim, additional, Feng, Zhi-Ping, additional, Tscharke, David, additional, and Vinuesa, Carola, additional

Published
2023
Full Text
View/download PDF

21. Additional file 1 of INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)

Author

Lam, Lyn Ley, Pavlakis, Nick, Shitara, Kohei, Sjoquist, Katrin M., Martin, Andrew J., Yip, Sonia, Kang, Yoon-Koo, Bang, Yung-Jue, Chen, Li-Tzong, Moehler, Markus, Bekaii-Saab, Tanios, Alcindor, Thierry, O’Callaghan, Christopher J., Tebbutt, Niall C., Hague, Wendy, Chan, Howard, Rha, Sun Young, Lee, Keun-Wook, Gebski, Val, Jaworski, Anthony, Zalcberg, John, Price, Timothy, Simes, John, and Goldstein, David

Abstract

Additional file 1: Spirit Checklist.

Published
2023
Full Text
View/download PDF

22. Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)

Author

Smith, Deborah, primary, Robledo, Kristy P., additional, Yip, Sonia, additional, Cummins, Michelle M., additional, Kok, Peey-Sei, additional, Lee, Yeh Chen, additional, Friedlander, Michael, additional, Baron-Hay, Sally, additional, Shannon, Catherine, additional, Coward, Jermaine, additional, Beale, Philip, additional, Goss, Geraldine, additional, Meniawy, Tarek, additional, Lombard, Janine, additional, Spurdle, Amanda B., additional, Andrews, John, additional, Stockler, Martin R., additional, Mileshkin, Linda, additional, and Antill, Yoland, additional

Published
2022
Full Text
View/download PDF

23. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

Author

Buteau, James P, primary, Martin, Andrew J, additional, Emmett, Louise, additional, Iravani, Amir, additional, Sandhu, Shahneen, additional, Joshua, Anthony M, additional, Francis, Roslyn J, additional, Zhang, Alison Y, additional, Scott, Andrew M, additional, Lee, Sze-Ting, additional, Azad, Arun A, additional, McJannett, Margaret M, additional, Stockler, Martin R, additional, Williams, Scott G, additional, Davis, Ian D, additional, Hofman, Michael S, additional, Akhurst, Tim, additional, Alipour, Ramin, additional, Banks, Patricia, additional, Beaulieu, Alexis, additional, Buteau, James P, additional, Chua, Wei, additional, Dhiantravan, Nattakorn, additional, Ford, Kate, additional, Gedye, Craig, additional, Goh, Jeffrey C, additional, Guminski, Alex, additional, Hamid, Anis, additional, Haskali, Mohammad B, additional, Hicks, Rodney J, additional, Hsiao, Edward, additional, Kirkwood, Ian D, additional, Kong, Grace, additional, Kwan, Edmond M, additional, Langford, Ailsa, additional, Lawrence, Nicola, additional, Lewin, Jeremy, additional, Lin, Peter, additional, McDonald, William, additional, Moodie, Kate, additional, Murphy, Declan G, additional, Ng, Siobhan, additional, Pattison, David A, additional, Pokorski, Izabella, additional, Ramdave, Shakher, additional, Ravi Kumar, Aravind S, additional, Redfern, Andrew D, additional, Rutherford, Natalie K, additional, Saghebi, Javad, additional, Spain, Lavinia, additional, Subramaniam, Shalini, additional, Tan, Thean Hsiang, additional, Thang, Sue Ping, additional, Tran, Ben, additional, Wallace, Roslyn, additional, Weickhardt, Andrew, additional, and Yip, Sonia, additional

Published
2022
Full Text
View/download PDF

24. CTNI-42. GENOME-WIDE DNA METHYLATION PATTERNS IN VERTU: A RANDOMIZED PHASE II TRIAL OF VELIPARIB, RADIOTHERAPY AND TEMOZOLOMIDE IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA

Author

Sim, Hao-Wen, primary, Lwin, Zarnie, additional, Barnes, Elizabeth, additional, McDonald, Kerrie, additional, Koh, Eng-Siew, additional, Rosenthal, Mark, additional, Foote, Matthew, additional, Back, Michael, additional, Wheeler, Helen, additional, Buckland, Michael, additional, Walsh, Kyle, additional, Fisher, Lauren, additional, Leonard, Robyn, additional, Hall, Merryn, additional, Ashley, David, additional, Yip, Sonia, additional, Simes, John, additional, Sulman, Erik, additional, and Khasraw, Mustafa, additional

Published
2022
Full Text
View/download PDF

25. CTIM-24. NUTMEG: A RANDOMIZED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH GLIOBLASTOMA

Author

Sim, Hao-Wen, primary, Lwin, Zarnie, additional, Barnes, Elizabeth, additional, McDonald, Kerrie, additional, Yip, Sonia, additional, Verhaak, Roel, additional, Heimberger, Amy, additional, Hall, Merryn, additional, Wong, Matthew, additional, Jennens, Ross, additional, Ashley, David, additional, Rosenthal, Mark, additional, Hovey, Elizabeth, additional, Ellingson, Benjamin, additional, Tognela, Annette, additional, Gan, Hui, additional, Back, Michael, additional, Koh, Eng-Siew, additional, Long, Anne, additional, Cuff, Katharine, additional, Begbie, Stephen, additional, Gedye, Craig, additional, Mislang, Anna, additional, Le, Hien, additional, Johnson, Margaret, additional, Kong, Benjamin, additional, Simes, John, additional, and Khasraw, Mustafa, additional

Published
2022
Full Text
View/download PDF

26. Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma

Author

Kong, Benjamin Y, primary, Sim, Hao-Wen, additional, Barnes, Elizabeth H, additional, Nowak, Anna K, additional, Hovey, Elizabeth J, additional, Jeffree, Rosalind, additional, Harrup, Rosemary, additional, Parkinson, Jonathon, additional, Gan, Hui K, additional, Pinkham, Mark B, additional, Yip, Sonia, additional, Hall, Merryn, additional, Tu, Emily, additional, Carter, Candace, additional, Koh, Eng-Siew, additional, Lwin, Zarnie, additional, Dowling, Anthony, additional, Simes, John S, additional, and Gedye, Craig, additional

Published
2022
Full Text
View/download PDF

27. Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours

Author

Lawrence, Nicola J., Chan, Howard, Toner, Guy, Stockler, Martin R., Martin, Andrew, Yip, Sonia, Wong, Nicole, Yeung, Annie, Mazhar, Danish, Pashankar, Farzana, Frazier, Lindsay, McDermott, Ray, Walker, Roderick, Tan, Hsiang, Davis, Ian D., Grimison, Peter, and on behalf of ANZUP

Published
2018
Full Text
View/download PDF

28. DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial.

Author

Forde, Patrick M., primary, Nowak, Anna K., additional, Kok, Peey-Sei, additional, Brown, Chris, additional, Sun, Zhuoxin, additional, Anagnostou, Valsamo, additional, O'Byrne, Kenneth John, additional, Yip, Sonia, additional, Cook, Alistair, additional, Lesterhuis, Willem Joost, additional, Hughes, Brett Gordon Maxwell, additional, Pavlakis, Nick, additional, Brahmer, Julie R., additional, Kindler, Hedy L., additional, Tsao, Anne S., additional, Zauderer, Marjorie Glass, additional, Ramalingam, Suresh S., additional, and Stockler, Martin R., additional

Published
2022
Full Text
View/download PDF

29. Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA).

Author

Smith, Deborah, Robledo, Kristy P., Yip, Sonia, Cummins, Michelle M., Kok, Peey-Sei, Lee, Yeh Chen, Friedlander, Michael, Baron-Hay, Sally, Shannon, Catherine, Coward, Jermaine, Beale, Philip, Goss, Geraldine, Meniawy, Tarek, Lombard, Janine, Spurdle, Amanda B., Andrews, John, Stockler, Martin R., Mileshkin, Linda, and Antill, Yoland

Subjects
PROGRAMMED death-ligand 1, IMMUNE checkpoint inhibitors, STAINS & staining (Microscopy), IMMUNOHISTOCHEMISTRY, WOMEN, ENDOMETRIAL tumors, RESEARCH funding, RECEIVER operating characteristic curves, PROGRESSION-free survival, SENSITIVITY & specificity (Statistics), IMMUNOTHERAPY, OVERALL survival
Abstract

Simple Summary: Until recently the outcome for women with advanced endometrial carcinoma has been poor. New immune therapies have resulted in much better outcomes for some, but not all, women with advanced disease. Determining which women are likely to respond is important, both to identify potential responders and prevent overtreatment of women who are not likely to respond. In this study we looked to see if there were any other markers that could be used to better predict those tumors that would be more likely to respond to the immune therapy known as durvalumab versus those tumors more likely to be resistant. Using statistical methods to evaluate each of the components examined we determined the cut-off point with the best performance. We found that the presence of tumor associated inflammatory cells had the strongest association with response. We also found that an algorithm derived from our best performing cut-off points identified women not likely to respond to treatment. While the presence of inflammatory cells was not significant when mismatch repair status was considered, our novel algorithm was. This is a small study and the findings do require validation in a larger group of women. Women with advanced endometrial carcinoma (EC) with mismatch repair (MMR) deficiency have improved outcomes when treated with immune checkpoint inhibitors; however, additional biomarkers are needed to identify women most likely to respond. Scores for programmed death ligand 1 (PD-L1), immunohistochemical staining of tumor (TC+), immune cells (IC+) and presence of tumor-associated immune cells (ICP) on MMR deficient (n = 34) and proficient (n = 33) EC from women treated with durvalumab in the PHAEDRA trial (ANZGOG1601/CTC0144) (trial registration number ACTRN12617000106336, prospectively registered 19 January 2017) are reported and correlated with outcome. Receiver operating characteristic (ROC) analyses and area under the ROC curve were used to determine optimal cutpoints. Performance was compared with median cutpoints and two algorithms; a novel algorithm derived from optimal cutpoints (TC+ ≥ 1 or ICP ≥ 10 or IC+ ≥ 35) and the Ventana urothelial carcinoma (UC) algorithm (either TC+ ≥ 25, ICP > 1 and IC+ ≥ 25 or ICP = 1 and IC+ = 100). The cutpoint ICP ≥ 10 had highest sensitivity (53%) and specificity (82%), being prognostic for progression-free survival (PFS) (p = 0.01), while the optimal cutpoints algorithm was associated with overall survival (p = 0.02); these results were not significant after adjusting for MMR status. The optimal cutpoints algorithm identified non-responders (p = 0.02) with high sensitivity (88%) and negative predictive value (92%), remaining significant after adjustment for MMR. Although MMR status had the strongest association with response, further work to determine the significance of ICP ≥ 10 and the novel optimal cutpoint algorithm is needed. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC).

Author

Pavlakis, Nick, primary, Shitara, Kohei, additional, Sjoquist, Katrin Marie, additional, Martin, Andrew James, additional, Jaworski, Anthony, additional, Yip, Sonia, additional, Oh, Do-Youn, additional, Moehler, Markus H., additional, Bekaii-Saab, Tanios S., additional, Simes, John, additional, and Goldstein, David, additional

Published
2022
Full Text
View/download PDF

31. CTLA4 Protects Against Maladaptive Cytotoxicity During Terminal Differentiation of Effector and Follicular CD4+ T Cells

Author

Hao, Yuwei, primary, Miraghazadeh, Bahar, additional, Chand, Rochna, additional, Davies, Ainsley R., additional, Cardinez, Chelisa, additional, Kwong, Kristy, additional, Downes, Morgan B., additional, Sweet, Rebecca A., additional, Cañete, Pablo F., additional, D’Orsogna, Lloyd J., additional, Fulcher, David A., additional, Choo, Sharon, additional, Yip, Desmond, additional, Peters, Geoffrey, additional, Yip, Sonia, additional, Witney, Matthew J., additional, Nekrasov, Maxim, additional, Feng, Zhi-Ping, additional, Tscharke, David C., additional, Vinuesa, Carola G., additional, and Cook, Matthew C., additional

Published
2022
Full Text
View/download PDF

32. Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—a phase 3 randomised trial

Author

Kok, Peey Sei, primary, Forde, Patrick M, additional, Hughes, Brett, additional, Sun, Zhuoxin, additional, Brown, Chris, additional, Ramalingam, Suresh, additional, Cook, Alistair, additional, Lesterhuis, Willem Joost, additional, Yip, Sonia, additional, O’Byrne, Ken, additional, Pavlakis, Nick, additional, Brahmer, Julie, additional, Anagnostou, Valsamo, additional, Ford, Kate, additional, Fitzpatrick, Karen, additional, Bricker, Alison, additional, Cummins, Michelle M, additional, Stockler, Martin, additional, and Nowak, Anna K, additional

Published
2022
Full Text
View/download PDF

33. LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study

Author

Kong, Benjamin Y, primary, Sim, Hao-Wen, additional, Nowak, Anna K, additional, Yip, Sonia, additional, Barnes, Elizabeth H, additional, Day, Bryan W, additional, Buckland, Michael E, additional, Verhaak, Roel, additional, Johns, Terrance, additional, Robinson, Cleo, additional, Thomas, Marc A, additional, Giardina, Tindaro, additional, Lwin, Zarnie, additional, Scott, Andrew M, additional, Parkinson, Jonathon, additional, Jeffree, Rosalind, additional, Lourenco, Richard de Abreu, additional, Hovey, Elizabeth J, additional, Cher, Lawrence M, additional, Kichendasse, Ganessan, additional, Khasraw, Mustafa, additional, Hall, Merryn, additional, Tu, Emily, additional, Amanuel, Benhur, additional, Koh, Eng-Siew, additional, and Gan, Hui K, additional

Published
2021
Full Text
View/download PDF

34. RTID-05. THE MULTI-ARM GLIOBLASTOMA AUSTRALASIA (MAGMA) TRIAL

Author

Kong, Benjamin, primary, Sim, Hao-Wen, additional, Koh, Eng-Siew, additional, Gan, Hui, additional, Barnes, Elizabeth H, additional, Yip, Sonia, additional, Nowak, Anna K, additional, Lau, Peter, additional, Cuff, Katharine, additional, Khoo, Eric, additional, Lwin, Zarnie, additional, Cooper, Adam, additional, Dowling, Anthony, additional, Linton, Anthony, additional, Harrup, Rosemary, additional, Dunlop, Tracey, additional, Hovey, Elizabeth, additional, Parkinson, Jonathon, additional, Jeffree, Rosalind, additional, Hall, Merryn, additional, Tu, Emily, additional, Andrew, Diana, additional, Simes, John, additional, and Gedye, Craig, additional

Published
2021
Full Text
View/download PDF

35. INNV-08. LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY

Author

Kong, Benjamin, primary, Sim, Hao-Wen, additional, Amanuel, Benhur, additional, Day, Bryan, additional, Buckland, Michael, additional, Verhaak, Roel, additional, Yip, Sonia, additional, Johns, Terrance, additional, Lwin, Zarnie, additional, Rosenthal, Mark, additional, Nowak, Anna K, additional, Barnes, Elizabeth H, additional, Scott, Andrew M, additional, Parkinson, Jonathon, additional, Jeffree, Rosalind, additional, Lourenco, Richard De Abreu, additional, Lau, Peter, additional, Whittle, James, additional, Hovey, Elizabeth, additional, Cher, Lawrence, additional, Kichendasse, Ganessan, additional, Hall, Merryn, additional, Robinson, Cleo, additional, Thomas, Marc, additional, Giardina, Tindaro, additional, Tu, Emily, additional, Khasraw, Mustafa, additional, Koh, Eng-Siew, additional, and Gan, Hui, additional

Published
2021
Full Text
View/download PDF

36. Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

Author

Sweeney, Christopher J., primary, Martin, Andrew J., additional, Stockler, Martin R., additional, Begbie, Stephen, additional, Chi, Kim N., additional, Chowdhury, Simon, additional, Coskinas, Xanthi, additional, Frydenberg, Mark, additional, Hague, Wendy E., additional, Horvath, Lisa G., additional, Joshua, Anthony M., additional, Lawrence, Nicola J., additional, Marx, Gavin M., additional, McCaffrey, John, additional, McDermott, Ray, additional, McJannett, Margaret, additional, North, Scott A., additional, Parnis, Francis, additional, Parulekar, Wendy, additional, Pook, David W., additional, Reaume, M. Neil, additional, Sandhu, Shahneen K., additional, Tan, Alvin, additional, Tan, Thean Hsiang, additional, Thomson, Alastair, additional, Tu, Emily, additional, Vera-Badillo, Francisco, additional, Williams, Scott G., additional, Yip, Sonia, additional, Zhang, Alison Y., additional, Zielinski, Robert R., additional, and Davis, Ian D., additional

Published
2021
Full Text
View/download PDF

37. Additional file 1 of MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)

Author

Siu, Ho Wai Derrick, Tebbutt, Niall, Chantrill, Lorraine, Karapetis, Chris, Steer, Christopher, Wilson, Kate, Espinoza, David, Bailey, Lisa, Yip, Sonia, Cuff, Jeff, Pavlakis, Nick, Thavaneswaran, Subotheni, Briscoe, Karen, Srivastav, Ratnesh, Shannon, Jennifer, Segelov, Eva, Tie, Jeannie, Caird, Susan, Francesconi, Alessandra, Price, Timothy, Wuttke, Melanie, Ladwa, Rahul, Sjoquist, Katrin, and Burge, Matthew

Subjects
Data_FILES
Abstract

Additional file 1.

Published
2021
Full Text
View/download PDF

39. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial

Author

Antill, Yoland, primary, Kok, Peey-Sei, additional, Robledo, Kristy, additional, Yip, Sonia, additional, Cummins, Michelle, additional, Smith, Deborah, additional, Spurdle, Amanda, additional, Barnes, Elizabeth, additional, Lee, Yeh Chen, additional, Friedlander, Michael, additional, Baron-Hay, Sally, additional, Shannon, Catherine, additional, Coward, Jermaine, additional, Beale, Philip, additional, Goss, Geraldine, additional, Meniawy, Tarek, additional, Lombard, Janine, additional, Andrews, John, additional, Stockler, Martin R, additional, and Mileshkin, Linda, additional

Published
2021
Full Text
View/download PDF

40. Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.

Author

Oar, Andrew, primary, Kneebone, Andrew, additional, Lee, Mark, additional, Goldstein, David, additional, Sjoquist, Katrin Marie, additional, Le, Hien, additional, Chu, Julie, additional, Barbour, Andrew, additional, Gholamrezaei, Leily, additional, Lynam, James F., additional, Bece, Andrej, additional, Bahamad, Sandra, additional, Yip, Sonia, additional, Espinoza, David, additional, Chantrill, Lorraine A., additional, Moore, Alisha, additional, Lee, Dominique, additional, Nguyen, Quoc Nam, additional, Samra, Jaswinder, additional, and Mumford, Jan, additional

Published
2021
Full Text
View/download PDF

41. Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).

Author

Smith, Deborah, primary, Robledo, Kristy, additional, Yip, Sonia, additional, Cummins, Michelle, additional, Kok, Peey-Sei, additional, Lee, Yeh Chen, additional, Friedlander, Michael, additional, Baron-Hay, Sally E., additional, Shannon, Catherine M., additional, Coward, Jermaine, additional, Beale, Philip James, additional, Goss, Geraldine, additional, Meniawy, Tarek, additional, Lombard, Janine Margaret, additional, Spurdle, Amanda B., additional, Andrews, John, additional, Stockler, Martin R., additional, Mileshkin, Linda R., additional, and Antill, Yoland Catherine, additional

Published
2021
Full Text
View/download PDF

42. DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial.

Author

Forde, Patrick M., primary, Nowak, Anna K., additional, Kok, Peey-Sei, additional, Brown, Chris, additional, Sun, Zhuoxin, additional, Anagnostou, Valsamo, additional, O'Byrne, Kenneth John, additional, Yip, Sonia, additional, Cook, Alistair, additional, Lesterhuis, Willem Joost, additional, Hughes, Brett Gordon Maxwell, additional, Pavlakis, Nick, additional, Brahmer, Julie R., additional, Kindler, Hedy L., additional, Tsao, Anne S., additional, Zauderer, Marjorie Glass, additional, Ramalingam, Suresh S., additional, and Stockler, Martin R., additional

Published
2021
Full Text
View/download PDF

43. A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylatedMGMTglioblastoma: the VERTU study

Author

Sim, Hao-Wen, primary, McDonald, Kerrie L, additional, Lwin, Zarnie, additional, Barnes, Elizabeth H, additional, Rosenthal, Mark, additional, Foote, Matthew C, additional, Koh, Eng-Siew, additional, Back, Michael, additional, Wheeler, Helen, additional, Sulman, Erik P, additional, Buckland, Michael E, additional, Fisher, Lauren, additional, Leonard, Robyn, additional, Hall, Merryn, additional, Ashley, David M, additional, Yip, Sonia, additional, Simes, John, additional, and Khasraw, Mustafa, additional

Published
2021
Full Text
View/download PDF

44. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Author

Hofman, Michael S, primary, Emmett, Louise, additional, Sandhu, Shahneen, additional, Iravani, Amir, additional, Joshua, Anthony M, additional, Goh, Jeffrey C, additional, Pattison, David A, additional, Tan, Thean Hsiang, additional, Kirkwood, Ian D, additional, Ng, Siobhan, additional, Francis, Roslyn J, additional, Gedye, Craig, additional, Rutherford, Natalie K, additional, Weickhardt, Andrew, additional, Scott, Andrew M, additional, Lee, Sze-Ting, additional, Kwan, Edmond M, additional, Azad, Arun A, additional, Ramdave, Shakher, additional, Redfern, Andrew D, additional, Macdonald, William, additional, Guminski, Alex, additional, Hsiao, Edward, additional, Chua, Wei, additional, Lin, Peter, additional, Zhang, Alison Y, additional, McJannett, Margaret M, additional, Stockler, Martin R, additional, Violet, John A, additional, Williams, Scott G, additional, Martin, Andrew J, additional, Davis, Ian D, additional, Dhiantravan, Nattakorn, additional, Ford, Kate, additional, Hofman, Michael S, additional, Langford, Ailsa, additional, Lawrence, Nicola, additional, McDonald, William, additional, Rana, Nisha, additional, Subramaniam, Shalini, additional, and Yip, Sonia, additional

Published
2021
Full Text
View/download PDF

45. DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer.

Author

Niazi, Tamim, primary, Williams, Scott, additional, Davis, Ian D., additional, Stockler, Martin R., additional, Martin, Andrew James, additional, Hague, Wendy, additional, Bracken, Karen, additional, Gorzeman, Margot, additional, Roncolato, Felicia, additional, Yip, Sonia, additional, Horvath, Lisa, additional, Sengupta, Shomik, additional, Hughes, Simon, additional, McDermott, Raymond S., additional, Catto, James WF, additional, Vapiwala, Neha, additional, Parulekar, Wendy R., additional, and Sweeney, Christopher, additional

Published
2020
Full Text
View/download PDF

46. MONARCC: A randomized phase II study of panitumumab monotherapy and panitumumab (pan) plus 5 Fluorouracil (FU) as first-line therapy for RAS and BRAF wild type metastatic colorectal cancer (mCRC): An AGITG clinical trial.

Author

Tebbutt, Niall C., primary, Steer, Christopher B., additional, Sjoquist, Katrin Marie, additional, Chantrill, Lorraine A., additional, Karapetis, Christos Stelios, additional, Nott, Louise M., additional, Espinoza, David, additional, Oostendorp, Martinus, additional, Yip, Sonia, additional, Cuff, Jeff, additional, and Burge, Matthew E., additional

Published
2020
Full Text
View/download PDF

47. Final Results of the Dream Trial: A Phase 2 Trial of Durvalumab with First-Line Chemotherapy in Mesothelioma with a Safety Run-In

Author

Nowak, Anna K., primary, Lesterhuis, W Joost, additional, Kok, Peey-Sei, additional, Brown, Chris, additional, Hughes, Brett GM, additional, Karikios, Deme J, additional, John, Thomas, additional, Kao, Steven C-H, additional, Leslie, Connull, additional, Cook, Alistair M, additional, Pavlakis, Nick, additional, Briscoe, Karen, additional, O’Byrne, Kenneth J, additional, Karapetis, Christos S, additional, Lam, Wei-Sen, additional, Langford, Ailsa, additional, Yip, Sonia, additional, and Stockler, Martin R, additional

Published
2020
Full Text
View/download PDF

49. ACTR-24. A RANDOMIZED PHASE II TRIAL OF VELIPARIB (V), RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS (PTS) WITH UNMETHYLATED MGMT (uMGMT) GLIOBLASTOMA (GBM): THE VERTU STUDY

Author

Khasraw, Mustafa, primary, Leanne McDonald, Kerrie, additional, Rosenthal, Mark, additional, Lwin, Zarnie, additional, Ashley, David, additional, Wheeler, Helen, additional, Barnes, Elizabeth, additional, Foote, Matthew, additional, Koh, Eng-Siew, additional, Sulman, Erik, additional, Back, Michael, additional, Buckland, Michael, additional, Sim, Hao-Wen, additional, Fisher, Lauren, additional, Leonard, Robyn, additional, Hall, Merryn, additional, Yip, Sonia, additional, and Simes, John, additional

Published
2019
Full Text
View/download PDF

50. Randomised Phase 3 Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) - INTEGRATE II

Author

Chua, Yu Jo, primary, Pavlakis, Nick, additional, Sjoquist, Katrin M., additional, Martin, Andrew J., additional, Tsobanis, Eric, additional, Yip, Sonia, additional, Bang, Yung-Jue, additional, Alcindor, Thierry, additional, O’callaghan, Christopher J., additional, Bekaii-Saab, Tanios S., additional, Grothey, Axel, additional, Chen, Li-Tzong, additional, Simes, John, additional, Zalcberg, John R., additional, Goldstein, David, additional, Komatsu, Yoshito, additional, Machida, Nozomu, additional, Esaki, Taito, additional, Hara, Hiroki, additional, and Shitara, Kohei, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results